EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Review of BCG immunotherapy for bladder cancer

George D Liatsos iD, Ilias Mariolis, Emilia Hadziyannis, Aristotelis Bamias, Dimitrios Vassilopoulos

Clinical Microbiology Reviews · 13.03.2025 · 38 (1)

DOI: 10.1128/cmr.00194-23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 13.03.2025. Verfasst von George D Liatsos und 4 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens "Hippokrati…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Adjuvants, Immunologic. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 255 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For several decades, intravesical Bacillus Calmette–Guérin (iBCG) immunotherapy has been the gold standard adjuvant treatment for high-risk and selected intermediate-risk patients with non-muscle-invasive bladder cancer (NMIBC). In this review, the mechanisms of iBCG immune-mediated anti-cancer activity and resistance are presented. Furthermore, a literature review of short-term and systemic iBCG-related side effects was performed. A high incidence (75.5%) of iBCG-related short-term, self-limiting adverse events was observed, while more severe iBCG-related local/systemic complications (iBCG-rL/SCs) that required medical treatment or hospitalization occurred at a lower rate (2.35%). Disseminated was the most common form of iBCG-rSCs, while two-thirds of the cases were classified as infectious. The implementation of molecular-based techniques resulted in significantly higher diagnostic rates. Anti-tuberculous treatment (ATT) is the mainstay of treatment, while in patients with any iBCG-rL/SC form involving the vasculature, ATT should be combined with surgery. Local and osteoarticular forms have the lowest mortality, but their management necessitates severe and debilitating surgical procedures. The overall iBCG-attributed mortality in patients with iBCG-rL/SC was 7.4%, with disseminated, vascular, and lung involvements exhibiting the highest rates. Given the global shortage of BCG for the last two decades, as well as the paucity of effective options for iBCG-refractory or relapsing NMIBC patients, new therapeutic strategies are being tested with promising early results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBCG VaccineImmunotherapyAdjuvants, ImmunologicHumansAdministration, Intravesical

Stichwörter der Autor:innen

BCGBCGitisadverse eventsbladder cancerimmunotherapy

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens "Hippokration", Athens, Greece.
  • 2nd Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Attikon University General Hospital, Athens, Greece.

ORCID-Profile: George D Liatsos

Zitieren

APA

Liatsos, G. D., Mariolis, I., Hadziyannis, E., Bamias, A., & Vassilopoulos, D. (2025). Review of BCG immunotherapy for bladder cancer. Clinical Microbiology Reviews, 38(1). https://doi.org/10.1128/cmr.00194-23

Vancouver

Liatsos GD, Mariolis I, Hadziyannis E, Bamias A, Vassilopoulos D. Review of BCG immunotherapy for bladder cancer. Clinical Microbiology Reviews. 2025;38(1). doi:10.1128/cmr.00194-23

BibTeX
@article{Liatsos2025,
  author = {Liatsos, George D and Mariolis, Ilias and Hadziyannis, Emilia and Bamias, Aristotelis and Vassilopoulos, Dimitrios},
  title = {Review of BCG immunotherapy for bladder cancer},
  journal = {Clinical Microbiology Reviews},
  year = {2025},
  volume = {38},
  number = {1},
  doi = {10.1128/cmr.00194-23}
}
Kostenlos starten →